» Articles » PMID: 35885536

Differentiating False Positive Lesions from Clinically Significant Cancer and Normal Prostate Tissue Using VERDICT MRI and Other Diffusion Models

Overview
Specialty Radiology
Date 2022 Jul 27
PMID 35885536
Authors
Affiliations
Soon will be listed here.
Abstract

False positives on multiparametric MRIs (mp-MRIs) result in many unnecessary invasive biopsies in men with clinically insignificant diseases. This study investigated whether quantitative diffusion MRI could differentiate between false positives, true positives and normal tissue non-invasively. Thirty-eight patients underwent mp-MRI and Vascular, Extracellular and Restricted Diffusion for Cytometry in Tumors (VERDICT) MRI, followed by transperineal biopsy. The patients were categorized into two groups following biopsy: (1) significant cancer—true positive, 19 patients; (2) atrophy/inflammation/high-grade prostatic intraepithelial neoplasia (PIN)—false positive, 19 patients. The clinical apparent diffusion coefficient (ADC) values were obtained, and the intravoxel incoherent motion (IVIM), diffusion kurtosis imaging (DKI) and VERDICT models were fitted via deep learning. Significant differences (p < 0.05) between true positive and false positive lesions were found in ADC, IVIM perfusion fraction (f) and diffusivity (D), DKI diffusivity (DK) (p < 0.0001) and kurtosis (K) and VERDICT intracellular volume fraction (fIC), extracellular−extravascular volume fraction (fEES) and diffusivity (dEES) values. Significant differences between false positives and normal tissue were found for the VERDICT fIC (p = 0.004) and IVIM D. These results demonstrate that model-based diffusion MRI could reduce unnecessary biopsies occurring due to false positive prostate lesions and shows promising sensitivity to benign diseases.

Citing Articles

Giving the prostate the boost it needs: Spiral diffusion MRI using a high-performance whole-body gradient system for high b-values at short echo times.

Molendowska M, Mueller L, Fasano F, Jones D, Tax C, Engel M Magn Reson Med. 2024; 93(3):1256-1272.

PMID: 39497447 PMC: 11680736. DOI: 10.1002/mrm.30351.


Precise Prostate Cancer Assessment Using IVIM-Based Parametric Estimation of Blood Diffusion from DW-MRI.

Balaha H, Ayyad S, Alksas A, Shehata M, Elsorougy A, Badawy M Bioengineering (Basel). 2024; 11(6).

PMID: 38927865 PMC: 11200510. DOI: 10.3390/bioengineering11060629.


MRI-based virtual pathology of the prostate.

Chatterjee A, Dwivedi D MAGMA. 2024; 37(4):709-720.

PMID: 38856839 DOI: 10.1007/s10334-024-01163-w.


Characteristic Mean Kurtosis Values in Simple Diffusion Kurtosis Imaging of Dentigerous Cysts.

Fukumura Y, Kuroda M, Yoshida S, Nakamura Y, Nakamitsu Y, Al-Hammad W Diagnostics (Basel). 2023; 13(24).

PMID: 38132203 PMC: 10742570. DOI: 10.3390/diagnostics13243619.

References
1.
Kitzing Y, Prando A, Varol C, Karczmar G, Maclean F, Oto A . Benign Conditions That Mimic Prostate Carcinoma: MR Imaging Features with Histopathologic Correlation. Radiographics. 2015; 36(1):162-75. PMC: 5496681. DOI: 10.1148/rg.2016150030. View

2.
Graham J, Kirkbride P, Cann K, Hasler E, Prettyjohns M . Prostate cancer: summary of updated NICE guidance. BMJ. 2014; 348:f7524. DOI: 10.1136/bmj.f7524. View

3.
Gibbs P, Pickles M, Turnbull L . Diffusion imaging of the prostate at 3.0 tesla. Invest Radiol. 2006; 41(2):185-8. DOI: 10.1097/01.rli.0000192418.30684.14. View

4.
Billis A . Prostatic atrophy. Clinicopathological significance. Int Braz J Urol. 2010; 36(4):401-9. DOI: 10.1590/s1677-55382010000400003. View

5.
Panagiotaki E, Walker-Samuel S, Siow B, Johnson S, Rajkumar V, Pedley R . Noninvasive quantification of solid tumor microstructure using VERDICT MRI. Cancer Res. 2014; 74(7):1902-12. DOI: 10.1158/0008-5472.CAN-13-2511. View